Emyria Secures First NSW Clinic Serving 2.5M in Western Sydney
Emyria secures New South Wales foothold with Matilda Healthcare partnership
Emyria has signed an agreement with Matilda Healthcare to establish an Empax clinic at Matilda Nepean Private Hospital in Kingswood, New South Wales. This marks the company’s third independent private hospital partner and entry into Australia’s most populous state, targeted for commencement in Q3 CY2026, subject to regulatory approvals.
The term sheet has been executed, with a formal licence agreement to follow. The partnership will establish four treatment rooms serving a Western Sydney catchment of more than 2.5 million people, with regional reach extending to Dubbo, Orange, Bathurst, Tamworth, and Mudgee.
Entry into New South Wales completes Emyria’s presence across all four major Australian states, de-risking geographic concentration and expanding the company’s addressable patient market. The expansion positions the company to serve patients across Western Australia, Queensland, Victoria, and New South Wales, covering Australia’s four most populous jurisdictions.
When big ASX news breaks, our subscribers know first
What is psychedelic-assisted therapy and why are clinics expanding?
Psychedelic-assisted therapy is an emerging treatment for patients with treatment-resistant mental health conditions, including PTSD and treatment-resistant depression, who have not responded to conventional therapies. The clinical model involves psychiatrist-supervised treatment delivered in licensed hospital settings with strict Schedule 8 drug management protocols.
Treatment requires Authorised Prescriber (AP) approvals from the Therapeutic Goods Administration (TGA). An AP is a medical practitioner who has received regulatory permission to prescribe otherwise restricted medicines, such as psilocybin or MDMA-based therapies, for specific clinical applications. Emyria’s Empax network operates under this framework, delivering assisted therapy programmes in controlled hospital environments with direct medical supervision.
The expansion of dedicated clinic infrastructure signals growing regulatory acceptance and psychiatrist support for these emerging therapies. Investors should understand this is a nascent but rapidly developing treatment category in Australia, with Emyria positioning itself as a national platform for advanced mental health therapies.
National footprint reaches 18 treatment beds across five sites
The addition of the Matilda Healthcare site expands Emyria’s Empax network to five locations across four jurisdictions, with a total treatment bed capacity of 18 beds once the New South Wales clinic is established. This geographic footprint provides national scale, which is critical for accelerating real-world data collection and supporting the recently announced Empax Global Partnership Programme for international drug sponsors.
| Site | State | Status | Beds |
|---|---|---|---|
| Perth (x2 centres) | Western Australia | Operating | Not specified |
| Brisbane (Avive) | Queensland | Operating | Not specified |
| Mornington Peninsula | Victoria | Operational Q2 CY26 | Not specified |
| Matilda Healthcare, Kingswood | New South Wales | Term sheet executed | 4 |
Scale matters for data collection and clinical trial infrastructure. The national footprint underpins the Empax Global Partnership Programme, which was announced on 20 April 2026 and positions Emyria as a partner for international drug development sponsors seeking Australian clinical trial infrastructure.
Authorised Prescriber network doubles to 12
Emyria’s Authorised Prescriber network has doubled following six new TGA approvals, increasing the total from six to 12 approved psychiatrists. The new approvals will support the Perth, Brisbane, and Mornington Peninsula clinics, expanding treatment capacity across the existing network.
A further eight psychiatrists are expected to attend New South Wales Empax training in June to support their AP applications. Clinical workforce recruitment for the New South Wales site has already commenced, as announced on 2 April 2026.
- Six new AP approvals received
- Total AP network now 12 (doubled)
- Eight psychiatrists expected to attend New South Wales training in June
- New South Wales recruitment proactively commenced
The doubling of AP numbers demonstrates psychiatrist acceptance of Emyria’s clinical governance and infrastructure. This is a lead indicator for treatment capacity growth, as each AP can supervise multiple patients across the Empax network.
Partnership terms and strategic alignment
The agreement with Matilda Healthcare includes key commercial and operational terms designed to support both parties while providing Emyria with competitive positioning in New South Wales.
- Initial term: 3 years, with two further options to renew (subject to Emyria satisfying a minimum utilisation condition)
- Licence fee: Payable on a monthly basis, with increased rates in year 2
- Exclusivity: Exclusive rights for psychedelic-assisted therapy at the facility, plus first right of refusal for other Matilda sites
- Operations: Empax provides the clinical team and care model; Matilda provides dedicated licensed hospital space, Schedule 8 licensure, secure storage, and drug management
Key commercial, confidentiality, exclusivity, and financial provisions are binding. The formal licence agreement will be negotiated as a priority.
Greg Hutchinson, Executive Chair
“Establishing an Empax clinic in New South Wales provides Emyria a presence in every major Australian State and Territory, and increases treatment room capacity to 18. Combined with the launch of the Empax Global Partnership Program and recent Authorised Prescriber approvals, this further expansion provides Emyria the national scale and clinical workforce to help deliver on our ambition to be the leading platform for advanced mental health therapies in Australia, and as a global partner for international drug development sponsors.”
Exclusive rights and first refusal provisions provide a competitive moat. The partnership model, where Emyria provides clinical expertise and the hospital partner provides infrastructure, is capital-light and replicable. This approach allows Emyria to scale its network without significant capital expenditure on property or hospital licensing.
The next major ASX story will hit our subscribers first
What comes next for Emyria
The New South Wales clinic is targeted for Q3 CY2026, subject to regulatory approvals. Execution of the formal licence agreement is a priority for the company. The expansion links directly to the Empax Global Partnership Programme announced on 20 April 2026, with national scale strengthening Emyria’s offering to international drug sponsors and clinical trial partners.
Real-world data collection will accelerate with the expanded network. As the number of treatment sites and Authorised Prescribers grows, Emyria’s ability to gather clinical outcomes data across a diverse patient population increases, supporting both its internal therapy development programmes and its partnership offering to external drug sponsors.
The New South Wales expansion is execution on a stated national growth strategy. Investors should watch for formal licence execution and clinic commencement milestones in Q3 CY2026 as key near-term catalysts.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to start receiving real-time alerts the moment market-moving announcements break.